Acrivon Therapeutics Inc (ACRV) USD0.001

Sell:$6.02Buy:$7.68$0.49 (7.53%)

Prices delayed by at least 15 minutes
Sell:$6.02
Buy:$7.68
Change:$0.49 (7.53%)
Prices delayed by at least 15 minutes
Sell:$6.02
Buy:$7.68
Change:$0.49 (7.53%)
Prices delayed by at least 15 minutes

Company Information

About this company

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Key people

Peter Blume-Jensen
Chairman of the Board, President, Chief Executive Officer
Rasmus Holm-Jorgensen
Chief Financial Officer
Eric Devroe
Chief Operating Officer
Kristina Masson
Executive Vice President - Business Operations, Director
Jean-Marie Cuillerot
Chief Medical Officer
Erick Gamelin
Chief Development Officer
Mary-Alice Miller
Chief Legal Officer
Charles M. Baum
Independent Director
Derek Dirocco
Independent Director
Ivana Magovcevic-Liebisch
Independent Director
Santhosh Palani
Independent Director
Sharon Shacham
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0048901096
  • Market cap
    $217.02m
  • Employees
    58
  • Shares in issue
    31.14m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.